Largest benefits seen for patients older than 60 years with no increased risk for hemorrhagic complications
Antithrombotic Therapy Not Helpful for COVID-19 Outpatients
Major adverse cardiopulmonary outcomes not reduced with aspirin, apixaban versus placebo for clinically stable COVID-19 outpatients
Aspirin Use Tied to Lower Rates of COVID-19 Infection
Adults using low-dose aspirin for primary or secondary prevention of CVD had lower likelihood of COVID-19 infection versus nonusers